concentration of n-3 pufa monohydroxylated derivatives in male adults with obesity after n-3 pufa supplementation.

Conditions: Obesity

Summary: the goal of this clinical trial is to learn if daily supplementation with spm active® can increase omega 3 polyunsaturated fatty acid derivatives and improve well-being in male adults with obesity. the main questions it aims to answer are: does 2 g/day of spm active® for 12 weeks increase plasma levels of 14-hydroxydocosahexaenoic (hdha), 17-hdha, and 18-hydroxy eicosapentaenoic acid (hepe)? does 2 g/day of spm active® for 12 weeks improve self-reported burnout, life satisfaction, and sleep quality? participants will: take two spm active® soft-gel capsules daily for 12 weeks (±2-4 days). provide 12-hour fasting blood samples before and after the intervention. complete validated surveys on burnout, life satisfaction, and sleep quality at baseline and study end.

purpose: this study aims to explore the effects of 'spm active®,' an omega-3 polyunsaturated fatty acid (n-3 pufa) dietary supplement, on male adults with obesity. the supplement specifically targets the increase of monohydroxylated derivatives of n-3 pufas, which play a crucial role in reducing chronic, low-grade inflammation. the primary objective of the study is to determine whether administering spm active® at 2g/day for a longer duration (3 months) leads to higher levels of the monohydroxylated derivatives (14-hdha, 17-hdha, and 18-hepe) in male adults with obesity (bmi between 30 and 40 kg/m\^2, n=33). the secondary objective is to evaluate whether administration of spm active® improves the following outcomes: a) burnout, b) life satisfaction, and c) sleep quality. these outcomes will be assessed using validated surveys administered before and after the intervention. participants: the study will include 33 healthy male participants of any ethnicity, aged 45-60 years, with a bmi of 30-40 kg/m\^2. procedures: the intervention involves the administration of the dietary supplement 'spm active®' provided by metagenics. all participants will take 2 soft gel capsules per day for 12 weeks, with a window of +/- 2-4 days. a 12-hour fasting blood sample will be collected from each participant before and after the intervention by a licensed phlebotomist at the unc nutrition research institute (nri) at kannapolis, nc. additionally, participants will complete surveys at the start and end of the study.

Eligibility criteria:
inclusion criteria: * male adults, ages 45-60 years * body mass index (bmi) between 30 and 40 kg/m\^2 * any race or ethnicity exclusion criteria: * age \ 60 years * biologically female sex * bmi \ 40 kg/m\^2 * diagnosed type 1 or type 2 diabetes * active autoimmune disease, liver disease, coagulopathy, or hypothyroidism * known allergy to fish or shellfish * current use of any of the following medications: asthma controller therapies, anticoagulants, estrogen or testosterone, daily aspirin or nsaids. * inability to give informed consent * receiving immunomodulatory or immunosuppressant therapy * known active malignancy or undergoing treatment for malignancy * use of n-3 pufa supplements or high consumption of fatty fish (\> 2 servings/week) within 3 months prior to enrollment.

Keywords: oxylipins obesity fish oil omega 3 fatty acids inflammation body mass index omega 3 fatty acid supplementation